ライフサイエンスコーパス: confidence

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 of 28% +/- 20% (scored on a scale of 0%-100% confidence).

2 xisting PTMs were fully quantified with high confidence.

3 er than a small to moderate benefit with 95% confidence.

4 gorized each diagnosis based on the level of confidence and assessed inter-observer agreement among g

5 nts reported a significant gap between their confidence and their actual performance in self-manageme

6 lls you something in great detail, with much confidence, and with emotion, it doesn't mean that it is

7 of the models and rigorously quantifying the confidence associated with the modeling results.

8 immunization risk (odds ratio [OR] 0.26, 95% confidence [CI] 0.11-0.64).

9 it is crucial that nursing students develop confidence communicating with others to improve patient

10 95% CI, 2.5-18.9) higher scores on patients' confidence compared with control group participants (P =

11 Decision confidence, consistency (primed vs unprimed), and qualit

12 ublished proteomic results, well-established confidence criteria should be reported for the detected

13 w it can be used as an additional measure of confidence for biomedical models.

14 arning model correctly identifies, with high confidence (>0.7), the low-temperature polymorph from it

15 ns of the DMN in both MEG and fMRI, boosting confidence in a possible pathophysiological role.

16 Our results increase confidence in existing measures of pollinator redundancy

17 When iMAR was used, the confidence in interpretation increased or stayed the sam

18 ng in positive FPIES OFCs and allow for more confidence in performing OFCs.

19 There was moderate to strong confidence in the ability to assess vascular calcific mo

20 Achieving confidence in the causality of a disease locus is a comp

21 and knowledge are rapidly evolving, there is confidence in the lasting value of meetings for medical

22 A person's apparent confidence in the likely reward of an action, for instan

23 failure was defined as no pixel value with a confidence index higher than 95% and/or no apparent shea

24 eparate, complementary assays to gain higher-confidence insights into cellular states.

25 ing SMR over time [odds ratio (OR) 1.73; 95% confidence interval (CI) 1.03-2.91; P = 0.03].

26 city versus non-Hispanic White (OR 1.10, 95% confidence interval (CI) 1.05-1.16), and care at a Natio

27 d with 30-day POM [odds ratio (OR) 1.71; 95% confidence interval (CI) 1.05-2.77); P = 0.032], whereas

28 [(+)transfusion: hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.09-1.30; (+)sepsis: HR 1.84,

29 sed risk of basal-like subtype [OR 4.17; 95% confidence interval (CI) 1.89-9.21] compared with both n

30 ere opioid-naive) had 9.2% higher costs [95% confidence interval (CI) 2.8%-15.6%; adjusted means $26,

31 ancer [adjusted odds ratios (OR) = 3.90, 95% confidence interval (CI) = 2.65-5.73].

32 eriority required the lower limit of the 95% confidence interval (CI) of the differences in CRs not e

33 resence by 1.5-fold (odds ratio [OR] = 1.56 [confidence interval (CI), 1.22-2.00]; P < 0.001) and 2-f

34 odds ratios (ORs) or beta-estimates with 95% confidence interval (CI).

35 nalysis to estimate risk ratio (RR) with 95% confidence interval (CI).

36 was reported in hazard ratios (HR) with 95% confidence interval (CI).

37 hildren was large in the NCDS [-0.37 SD, 95% confidence interval (CI): -0.46, -0.27] and in the BCS (

38 loped new vessels, odds ratio (OR) 0.12 [95% confidence interval (CI): 0.01, 1.03].

39 s. lowest (1st), odds ratio (OR) = 0.66, 95% confidence interval (CI): 0.45, 0.98; P for trend = 0.05

40 second quintile hazard ratio (HR)=1.03 [95% confidence interval (CI): 0.86, 1.25]; third quintile HR

41 able-adjusted relative risk (RR) = 0.99, 95% confidence interval (CI): 0.90, 1.09), skin tanning abil

42 ) for ER visits for GI illness was 1.09 [95% confidence interval (CI): 1.03, 1.16] in the 10-14 d per

43 h AF (adjusted hazard ratio (HR) = 1.19, 95% confidence interval (CI): 1.03, 1.38).

44 tumors (pooled odds ratio (pOR) = 1.32, 95% confidence interval (CI): 1.10, 1.58).

45 usted incidence rate ratio (IRR) = 1.86, 95% confidence interval (CI): 1.27, 2.71; for infected wound

46 uccessful agers (N = 789) reported 3.79 (95% confidence interval (CI): 1.39-6.19) minutes more daily

47 first quartile, odds ratio (OR) = 2.70, 95% confidence interval (CI): 1.55, 4.70) and current smoker

48 t the infection attack rates were 78.0% (95% confidence interval (CI): 63.5-86.3%) in French Polynesi

49 e cancer registries (sensitivity of 89%, 95% confidence interval (CI): 86, 92).

50 for women undergoing CPM (BCSS: HR 1.08, 95% confidence interval 1.01-1.16; OS: HR 1.08, 95% confiden

51 fidence interval 1.01-1.16; OS: HR 1.08, 95% confidence interval 1.03-1.14), regardless of HR status

52 the resection group (relative risk 3.01, 95% confidence interval 1.15-7.90).

53 ted to neovascular AMD (odds ratio 1.55 [95% confidence interval 1.31-1.84], P = 2.67 x 10(-7)).

54 ian cancer-related survival was 37.7 months (confidence interval 29-46 mo).

55 ed 4-year event-free survival was 89.7% (95% confidence interval 84.1-95.2%) and overall survival was

56 he highest accuracy (97%, 34 of 35 eyes, 95% confidence interval 92%-100%) for classifying an eye as

57 lower risks of BCC (hazard ratio = 0.6; 95% confidence interval = 0.4-0.9) but significantly higher

58 l monthly mean (prevalence ratio = 1.31 [95% confidence interval = 1.05-1.63] per kJ/m(2)) and minimu

59 est statistic [df] = 6.58 [1], P = 0.01; 95% confidence interval = 1.06 to 1.55).

60 higher risks of SCC (hazard ratio = 2.3; 95% confidence interval = 1.5-3.6).

61 ce interval [0.77, 0.88], vertical 0.76, 95% confidence interval [0.68, 0.82]).

62 correlation coefficient horizontal 0.83, 95% confidence interval [0.77, 0.88], vertical 0.76, 95% con

63 r creatinine, we found y = 0.73x - 1.55 (95% confidence interval [95% CI] slope, 0.71-0.76), giving t

64 quartile hazard ratio for DDKF was 2.47 (95% confidence interval [95% CI], 1.21-5.05).

65 0.24 to 0.10 (adjusted risk ratio 0.44, 95% confidence interval [CI] 0.26-0.75).

66 pared to AA adults (odds ratio [OR] 0.50 95% confidence interval [CI] 0.31-0.79, P = 0.003), schoolch

67 difference of 15.8 percentage points; 97.5% confidence interval [CI] 0.5-31.2; P = .021).

68 al safety climate (Odds Ratio [OR]=2.76, 95% Confidence Interval [CI] 1.51-5.03), people-oriented cul

69 h vivax malaria within 1 year was 33.8% (95% confidence Interval [CI] 33.1%-34.5%) after initial mono

70 ase in the CT (32% decrease in DTN time, 95% confidence interval [CI] 38%-55%), stretcher to CT (30%

71 Overall SVR rates were 89.8% (95% confidence interval [CI] 89.2-90.4) in white, 89.8% (95%

72 HBVr (adjusted hazard ratio [HR] = 5.14; 95% confidence interval [CI] = 1.77-14.92; P = .003).

73 e in event rates, 0.7 percentage points; 95% confidence interval [CI], -1.5 to 2.8; P=0.007 for nonin

74 eighted imaging-derived AAR (bias, 0.18; 95% confidence interval [CI], -1.6 to 1.3) and AAR derived f

75 deficits (26%) had worse 6MWD = -109 m (95% confidence interval [CI], -175 to -43), London Chest Act

76 ne group; between-group difference, 0.0; 95% confidence interval [CI], -2.0 to 2.1) or the Tiredness

77 p duration (1-year change in LVEF -3.6%; 95% confidence interval [CI], -4.4% to -2.8%; 3-year change

78 zure frequency, -22.8 percentage points; 95% confidence interval [CI], -41.1 to -5.4; P=0.01).

79 eight in the surgery group was -45.0 kg (95% confidence interval [CI], -47.2 to -42.9; mean percent c

80 was estimated to have ranged from 0.3% (95% confidence interval [CI], .1%-1.9%; 1 of 284 participant

81 either regimen (hazard ratio [HR], 0.43; 95% confidence interval [CI], .33-.57) and attainment of sus

82 D in Australia almost halved (IRR, 0.53; 95% confidence interval [CI], .50-.57), but differed by PCV

83 Comparative effectiveness was 24.0% (95% confidence interval [CI], .6%-42%); there was evidence o

84 ears (adjusted odds ratios [aOR] = 0.21; 95% confidence interval [CI], 0.05 to 0.97), 50-64 years (aO

85 o progression (relative risk [RR], 0.32; 95% confidence interval [CI], 0.06-1.85; I(2) = 0%) and of w

86 ean logMAR VA improvement of 0.17 units, 95% confidence interval [CI], 0.12-0.20, P < 0.01), whereas

87 te of </=20/200 was 0.66/eye-year (EY), (95% confidence interval [CI], 0.32/EY to 1.22/EY); the rate

88 tients, the hazard ratio (HR) was 0.543 (95% confidence interval [CI], 0.321-0.918; P = .021), with m

89 n the control group (relative risk, 1.6; 95% confidence interval [CI], 0.4 to 6.8; absolute differenc

90 ander resuscitation (hazard ratio, 0.62; 95% confidence interval [CI], 0.47 to 0.82), as well as a lo

91 with sorafenib (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.57-0.77), being seen at a Na

92 s yielded areas under the curve of 0.72 (95% confidence interval [CI], 0.65 to 0.79) for the SPIROMIC

93 tients with PAD (hazard ratio [HR] 0.79; 95% confidence interval [CI], 0.66-0.94; P=0.0098) and witho

94 63 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the

95 n the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intent

96 al mortality (odds ratio, 1.04 per hour; 95% confidence interval [CI], 1.02 to 1.05; P<0.001), as was

97 7% in 2014 (prevalence ratio [PR], 1.05; 95% confidence interval [CI], 1.03-1.07).

98 azard ratio [HR], 1.10 per 10% increase; 95% confidence interval [CI], 1.04-1.16), low CSF to blood g

99 arization cumulative incidence was 2.3% (95% confidence interval [CI], 1.1-3.4), 3.5% (95% CI, 2.1-5.

100 /=18 years of age (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2-2.7), black race (OR, 1.5;

101 increase in age (odds ratio [OR], 1.44; 95% confidence interval [CI], 1.20-1.72; P < 0.01).

102 MUNO) subjects (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.22-1.37) and metabolically u

103 low (adjusted hazard ration [aHR], 1.55, 95% confidence interval [CI], 1.34-1.8) and medium (aHR, 1.2

104 t varenicline (relative risk [RR]: 2.64; 95% confidence interval [CI], 1.34-5.21) and bupropion (RR:

105 as 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7).

106 an fold rise from baseline [GMFR] = 1.6 [95% confidence interval [CI], 1.4,1.7], P value < .0001) and

107 es; standardized mean differences, 2.07; 95% confidence interval [CI], 1.44 to 2.69), but not minutes

108 loss of ZIKV RNA detection were 14 days (95% confidence interval [CI], 11 to 17) and 54 days (95% CI,

109 urveyed, there were 646 patients (11.9%; 95% confidence interval [CI], 11.1%-12.8%) with 727 distinct

110 Overall 2013-2014 incidence was 17.8 (95% confidence interval [CI], 16.6-19.2) cases per 100000 pe

111 rnal GBS colonization worldwide was 18% (95% confidence interval [CI], 17%-19%), with regional variat

112 neumocystis DNA was identified in 25.7% (95% confidence interval [CI], 17.8%-33.7%) of newborns studi

113 ly associated with systolic (4.58 mm Hg; 95% confidence interval [CI], 2.64-6.51) and diastolic (2.25

114 ted with increased risk of RD was 12.42 (95% confidence interval [CI], 2.91-53.01; P = 0.001) for eye

115 n overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0).

116 acute erythema migrans ranged from 36% (95% confidence interval [CI], 25%-50%) to 54% (95% CI, 42%-6

117 djusted VE against A(H1N1)pdm09 was 43% (95% confidence interval [CI], 25%-57%).

118 inverse Simpson's alpha-diversity, 5.03; 95% confidence interval [CI], 4.08-6.14) than in the placebo

119 We estimated that 14.1% (95% confidence interval [CI], 6.3-21.9%) of HPV DNA detectio

120 5% during the index MI admission, 66.8% (95% confidence interval [CI], 65.9-67.8) had EF reassessment

121 ears of follow-up (implant: 11.9 points; 95% confidence interval [CI], 8.6-15.2; P < 0.001; systemic:

122 RNA with a diagnostic accuracy of 94.8% (95% confidence interval [CI], 89.4 to 97.6), a sensitivity o

123 and negative predictive value of 96.0% (95% confidence interval [CI], 90.2% to 98.9%), 65.9% (95% CI

124 age of agreement was excellent at 99.0% (95% confidence interval [CI], 98.6% to 99.2%; kappa, 0.89),

125 CA is rare (weighted prevalence = 0.03%; 95% confidence interval [CI]: 0.01% to 0.04%) compared with

126 (14.3% vs. 33.3%; odds ratio [OR]: 0.33, 95% confidence interval [CI]: 0.114-0.978).

127 e death and MI (hazard ratio [HR]: 0.65; 95% confidence interval [CI]: 0.50 to 0.84; p = 0.001), alth

128 core and all mortality predictors: 0.76; 95% confidence interval [CI]: 0.62 to 0.92; p = 0.005), wher

129 ecline in eGFR (hazard ratio [HR]: 0.77; 95% confidence interval [CI]: 0.66 to 0.89; p < 0.001), doub

130 andmark (year 1 hazard ratio [HR]: 0.82; 95% confidence interval [CI]: 0.67 to 0.99; year 2 HR: 0.90;

131 ) for asthma ranging from 1.25 for PFOS (95% Confidence Interval [CI]: 0.90, 1.72) to 4.01 for PFDA (

132 the diagnosis of appendicitis was 0.97 (95% confidence interval [CI]: 0.95, 1.00) for PSV and 0.86 (

133 female subjects (odds ratio [OR]: 1.75, 95% confidence interval [CI]: 1.08-2.83, P-value<0.05).

134 (16%; ratio of averaged risk [RAR]: 3.2; 95% confidence interval [CI]: 1.5 to 7.5), LMWH and VKA (16%

135 General obesity (OR = 5.94, 95% confidence interval [CI]: 3.69-9.55) and central obesity

136 hypertension among US adults was 45.6% (95% confidence interval [CI]: 43.6% to 47.6%) and 31.9% (95%

137 1119 patients, pooled CTT was 58 hours (95% confidence interval [CI]: 50-65 hours).

138 age sensitivity and specificity was 68% (95% confidence interval [CI]: 59%, 76%) and 75% (95% CI: 71%

139 uivalence (ABE) acceptance criteria of a 90% confidence interval contained within the confidence limi

140 The 95% confidence interval for RMS diameters is 5.48 +/- 1.76 m

141 to 1.58; P=0.53); the upper limit of the 95% confidence interval for the difference in event rates fe

142 s (0.97 and 0.76 diopters, respectively; 90% confidence interval for treatment difference, -0.23 to 0

143 uoroscopic nephrostogram results, with a 95% confidence interval of 69.2% and 100%.

144 area with a loss less than first-percentile confidence interval of the variability in this group.

145 as not significantly greater than 0, but the confidence interval was predominantly positive (M=0.019;

146 ive intervention (rate ratio [RR], 0.05 [95% confidence interval {CI}, .01-.38]).

147 sis was predictive of reduced SVR (0.51 [95% confidence interval {CI}, .31-.87]; P = .01).

148 eased significantly for SSTI (aOR, 0.85 [95% confidence interval {CI}, .76-.95]) and respiratory infe

149 osis (adjusted hazard ratio [aHR], 1.42 [95% confidence interval {CI}, .96-2.11]; aHR, 1.66 [95% CI,

150 ng etiology (overall weighted AF, 40.3% [95% confidence interval {CI}, 37.6%-44.3%]), though the AF w

151 among protein coding genes: 23.5%-59.3% (95% confidence interval) of highly expressed genes with dist

152 s (standardized mean difference = -0.32 [95% confidence interval, -0.44 to -0.19]).

153 1-2.53; P = 0.76; risk difference, 3.1%; 95% confidence interval, -16.2 to 10.1).

154 t risk of FMT failure (odds ratio, 0.15; 95% confidence interval, .007-.40).

155 (14 deaths; incidence rate ratio, 0.31 [95% confidence interval, .16-.61]; P = .0003), when most dea

156 nfectious units per million cells (IUPM; 95% confidence interval, 0.26-0.55 IUPM), 3-fold lower than

157 nmatched population (hazard ratio, 0.57; 95% confidence interval, 0.33-0.98; P=0.04).

158 dification patients (hazard ratio, 0.54; 95% confidence interval, 0.36-0.82).

159 , adjunct vs. control; odds ratio, 0.89; 95% confidence interval, 0.46-1.74; P = 0.733).

160 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.53; P = 0.76; risk differenc

161 61-0.78) and sisters hazard ratios=0.65 (95% confidence interval, 0.52-0.80), respectively.

162 after LVAD (adjusted hazard ratio, 0.73; 95% confidence interval, 0.58-0.92; P=0.007).

163 nce between brothers hazard ratios=0.69 (95% confidence interval, 0.61-0.78) and sisters hazard ratio

164 myocardial infarction (odds ratio, 0.76; 95% confidence interval, 0.61-0.94; P=0.01) compared with CA

165 thout any masked hypertension was 0.681 (95% confidence interval, 0.640-0.723) for ASCVD risk and 0.7

166 , 0.640-0.723) for ASCVD risk and 0.703 (95% confidence interval, 0.663-0.744) for clinic systolic BP

167 omized to PCI alone (hazard ratio, 0.84; 95% confidence interval, 0.70-1.01; P=0.06).

168 een the PSF and the PSFEARL DS was 0.82 (95% confidence interval, 0.73-0.91) for i-PET and 0.89 (95%

169 a survival benefit (hazard ratio, 0.82; 95% confidence interval, 0.75-0.90; P<0.001).

170 the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferi

171 interval, 0.73-0.91) for i-PET and 0.89 (95% confidence interval, 0.81-0.96) for EoT-PET.

172 0.46) or amlodipine (hazard ratio, 0.93; 95% confidence interval, 0.84-1.03; P=0.16) was not associat

173 o either lisinopril (hazard ratio, 1.04; 95% confidence interval, 0.94-1.15; P=0.46) or amlodipine (h

174 rd ICD RPM patients (hazard ratio, 1.06; 95% confidence interval, 0.94-1.19; P=0.34).

175 sychosocial factors (hazard ratio, 1.14; 95% confidence interval, 0.96-1.35), the association was att

176 d retrieval technique (odds ratio, 1.08; 95% confidence interval, 1.05-1.10; P<0.001).

177 utional volume of BAV (odds ratio, 1.58; 95% confidence interval, 1.06-2.37; P=0.03).

178 mortality (P = 0.003; odds ratio, 1.254; 95% confidence interval, 1.078-1.457).

179 fect was attenuated (hazard ratio, 1.16; 95% confidence interval, 1.08-1.25; P<0.001).

180 asthma at baseline (hazard ratio, 1.51; 95% confidence interval, 1.08-2.10) after adjusting for conf

181 per year (odds ratio for increase, 1.17; 95% confidence interval, 1.09-1.27) from fiscal year 2000 th

182 s <limit of detection; odds ratio, 1.50; 95% confidence interval, 1.09-2.07), but not with decline in

183 al outcome (adjusted relative risk, 1.6; 95% confidence interval, 1.1-2.5; P=0.02).

184 eyond traditional risk (odds ratio, 6.0; 95% confidence interval, 1.1-31.7; P=0.03).

185 y associated with STDR (odds ratio, 2.3; 95% confidence interval, 1.1-4.9; P = 0.04).

186 istory of sudden death (odds ratio, 3.2; 95% confidence interval, 1.1-9.4) were independently associa

187 confounding factors (hazard ratio, 1.69; 95% confidence interval, 1.10-2.61; P = 0.018).

188 for fourth versus first quartile, 1.81; 95% confidence interval, 1.11 to 2.96; Ptrend=0.04).

189 talization (adjusted hazard ratio, 1.34; 95% confidence interval, 1.11-1.60; P=0.002) and death (haza

190 isk of graft failure 3.59 times as high (95% confidence interval, 1.12 to 15.94) as that of patients

191 HIV was associated with LBW (aRR = 1.74; 95% confidence interval, 1.18, 2.58; P < .01).

192 h survival (adjusted relative risk, 1.7; 95% confidence interval, 1.2-2.6; P=0.007) and survival with

193 d hazard ratio for publication was 1.79 (95% confidence interval, 1.20-2.67) in favor of licensed dru

194 In 3% of cases (95% confidence interval, 1.3%-6.7%), there was clinically me

195 event-40% higher than expected (SHR=1.4, 95% confidence interval, 1.3-1.4).

196 ted annual incidence of 1.8 per 100 000 (95% confidence interval, 1.3-2.2) between 1990 and 2014.

197 increased odds of cardioembolic stroke (95% confidence interval, 1.39-4.58; P=2.7x10(-3)).

198 <0.001), coagulopathy (odds ratio, 2.19; 95% confidence interval, 1.51-3.18; P<0.001), and low instit

199 omy (vs duct-to-duct) (odds ratio, 3.06; 95% confidence interval, 1.52-6.16; P = 0.002).

200 x 10(5) particles/ml higher carbon load (95% confidence interval, 1.56 x 10(5) to 9.10 x 10(5) partic

201 omparing blacks versus whites were 2.61 (95% confidence interval, 1.57-4.34) and 1.79 (1.06-3.03), re

202 Prior syncope (odds ratio, 4.0; 95% confidence interval, 1.6-9.7) and a family history of su

203 P=0.002) and death (hazard ratio, 2.10; 95% confidence interval, 1.60-2.75; P<0.001) increased in th

204 cific death (adjusted hazard ratio, 2.3; 95% confidence interval, 1.7-3.0; P < 0.001).

205 variable) showed a hazard ratio of 2.25 (95% confidence interval, 1.70-2.99) after adjusting for othe

206 l, 4.7-55.9) and COPD (odds ratio, 5.76; 95% confidence interval, 1.9-17.4), but not asthma alone.

207 onfidence interval, 42% to 67%] and 14% [95% confidence interval, 11% to 18%] higher hospitalization

208 by positive serum HBsAg, of 2.9% (upper 95% confidence interval, 19%).

209 of developing AF was 21.99 times higher (95% confidence interval, 19.26-25.12) in patients with CHD t

210 d >7 beats (adjusted hazard ratio, 6.26; 95% confidence interval, 2.02-19.41; P=0.0015).

211 r the primary composite outcome of 3.52 (95% confidence interval, 2.17 to 5.71).

212 ricular assist device (odds ratio, 3.48; 95% confidence interval, 2.25-5.36; P<0.001), coagulopathy (

213 receiving preferred beta-lactam therapy (95% confidence interval, 2.4-8.2; P < .0001).

214 ter contribution to xylem water) is 37% (95% confidence interval, 28-46%).

215 ment was associated with VF (SHR, 11.50 [95% confidence interval, 3.92-33.74]; P < .001).

216 er minute (adjusted hazard ratio, 15.63; 95% confidence interval, 4.01-60.89; P<0.0001) and >7 beats

217 ere cardiogenic shock (odds ratio, 6.01; 95% confidence interval, 4.19-8.61; P<0.001), need for left

218 associated with ACOS (odds ratio, 16.3; 95% confidence interval, 4.7-55.9) and COPD (odds ratio, 5.7

219 ly worse for the OAC alone group: 67.1% (95% confidence interval, 40.9%-83.6%) versus 94.1% (95% conf

220 ged 18-34 years and >/=75 years had 54% [95% confidence interval, 42% to 67%] and 14% [95% confidence

221 fter a single ablation procedure of 54% (95% confidence interval, 43%-68%) in the PVI-only and 57% (9

222 erval, 43%-68%) in the PVI-only and 57% (95% confidence interval, 46%-72%) in the Substrate-modificat

223 ian overall survival (OS) was 30 months (95% confidence interval, 6-54) from start of midostaurin.

224 nce interval, 40.9%-83.6%) versus 94.1% (95% confidence interval, 65%-99.1%) for the OAC plus intravi

225 nfidence interval, 89.2-99.4) and 86.2% (95% confidence interval, 78.7-94.5), respectively.

226 al and disease-free survival were 94.2% (95% confidence interval, 89.2-99.4) and 86.2% (95% confidenc

227 was achieved by 98% of patients (51/52; 95% confidence interval, 90%-100%).

228 eoperative experience (difference, 20.0; 95% confidence interval, CI, 16.6-23.3).

229 noninferiority was based on a 1-sided 97.5% confidence interval.

230 poverty at age 7-14 years (beta = -0.01, 95% confidence interval: -0.04, 0.01) and school attendance/

231 ars (i.e., joint mediators beta = -0.07, 95% confidence interval: -0.12, -0.02) than the indirect eff

232 indicators; n = 5,292; 30%) had a 2.2% (95% confidence interval: -0.3% to 4.6%) absolute risk reduct

233 447 HU +/- 166, respectively [P = .241]; 95% confidence interval: -15.1, 60.0), including those from

234 uction in odds of CAD (odds ratio: 0.66; 95% confidence interval: 0.44 to 0.98; p = 0.04).

235 .84-1.37) and VNTR 7 DRD4 (odds ratio: 0.68; confidence interval: 0.47-1.00).

236 ated with better OS (hazard ratio 0.569, 95% confidence interval: 0.478-0.677, P < 0.001) independent

237 -2.37) and VNTR 10 SLC6A3 (odds ratio: 0.74; confidence interval: 0.60-0.90), whereas the following v

238 nificant: rs1947274 LPHN3 (odds ratio: 0.95; confidence interval: 0.71-1.26), rs5661665 LPHN3 (odds r

239 was reduced by 13% (hazard ratio = 0.87, 95% confidence interval: 0.79, 0.96).

240 ated with a decrement of 3.70 IQ points (95% confidence interval: 0.83, 6.56).

241 71-1.26), rs5661665 LPHN3 (odds ratio: 1.07; confidence interval: 0.84-1.37) and VNTR 7 DRD4 (odds ra

242 y-stable DII group (hazard ratio = 1.32, 95% confidence interval: 1.01, 1.74).

243 mprovements (incidence rate ratio, 1.04; 95% confidence interval: 1.02, 1.07) (P = .002).

244 .17), and for low frequency/HF was 1.08 (95% confidence interval: 1.03 to 1.14).

245 ivariable-adjusted relative risk = 1.09, 95% confidence interval: 1.04, 1.14; P for trend < 0.001) we

246 2-2.55), rs4680 COMT (odds ratio (OR): 1.40; confidence interval: 1.04-1.87), rs5569 SLC6A2 (odds rat

247 nterval: 1.08 to 1.21), for HF was 1.12 (95% confidence interval: 1.06 to 1.17), and for low frequenc

248 ivariable-adjusted relative risk = 1.10, 95% confidence interval: 1.06, 1.15; P for trend < 0.001) an

249 normal-to-normal RR intervals was 1.14 (95% confidence interval: 1.08 to 1.21), for HF was 1.12 (95%

250 s (SNPs) rs1800544 ADRA2A (odds ratio: 1.69; confidence interval: 1.12-2.55), rs4680 COMT (odds ratio

251 ndem repeat (VNTR) 4 DRD4 (odds ratio: 1.66; confidence interval: 1.16-2.37) and VNTR 10 SLC6A3 (odds

252 the combined endpoint (odds ratio: 2.73; 95% confidence interval: 1.2 to 5.9; p = 0.01).

253 diovascular disease (hazard ratio = 1.4, 95% confidence interval: 1.2, 1.6), compared with men with a

254 1.04-1.87), rs5569 SLC6A2 (odds ratio: 1.73; confidence interval: 1.26-2.37) and rs28386840 SLC6A2 (o

255 se hospitalizations (hazard ratio = 1.5, 95% confidence interval: 1.4, 1.6) and cardiovascular diseas

256 37) and rs28386840 SLC6A2 (odds ratio: 2.93; confidence interval: 1.76-4.90), and, repeat variants va

257 gest predictor of OD (odds ratio = 14.8; 95% confidence interval: 12.7-17.2).

258 rical comparison group (odds ratio: 4.0; 95% confidence interval: 2.08 to 7.7; p < 0.0001).

259 s discovered at prophylactic mastectomy (95% confidence interval: 69.5%, 82.4%) and 90.0% excluding t

260 2.4%) and 90.0% excluding those cancers (95% confidence interval: 83.3%, 93.7%).

261 ronary atherosclerotic burden (increase [95% confidence interval] in rank of plaque volume for each 1

262 nd apolipoprotein B (change in SD units [95% confidence interval]: -0.98 [-1.11, -0.86]) with similar

263 protein cholesterol (change in SD units [95% confidence interval]: -1.01 [-1.14, -0.88]), remnant cho

264 remnant cholesterol (change in SD units [95% confidence interval]: -1.03 [-1.17, -0.89]), and apolipo

265 nce (SMD) of thyroid hormone levels with 95% confidence intervals (95% CI) obtained from the studies

266 ious infection; the incidence rates with 95% confidence intervals (CI) per 1,000 person-years were as

267 ecurrences and hazard ratios (HRs), with 95% confidence intervals (CI), for the time-dependent risk r

268 We estimated odds ratios (ORs) and 95% confidence intervals (CIs) by logistic regression with a

269 ecific mortality rate ratios (MRRs) with 95% confidence intervals (CIs) for all-cause and liver-relat

270 sed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific mortality

271 Hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome were extract

272 multivariate-adjusted hazard ratios and 95% confidence intervals (CIs) for FI risk in women receivin

273 We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for TBI in a Cox regression,

274 was used to estimate relative risks and 95% confidence intervals (CIs) from Cox proportional hazards

275 a statistically significant difference; 95% confidence intervals (CIs) were calculated.

276 estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs).

277 hildren in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]).

278 adjusted hazard ratios 0-14 years: 1.51 [95% confidence intervals 1.19 to 1.90]; 15-24 years: 1.37 [1

279 ts were estimated with hazard ratios and 95% confidence intervals computed in Cox regressions.

280 ma incidence, melanoma hazard ratios and 95% confidence intervals for lithium exposure were estimated

281 stimation provided prevalence ratios and 95% confidence intervals of ERG expression in relation to pa

282 the optimal motif length and calculating the confidence intervals of estimated parameters.

283 ions were estimated by hazard ratios and 95% confidence intervals using Cox models adjusted for confo

284 en had lower survival; hazard ratios and 95% confidence intervals were 1.63 (1.27-2.08), 1.38 (1.11-1

285 ntensive compared with the standard arm (95% confidence intervals) were 1.18 (0.40 to 3.33), 1.61 (0.

286 riminate CA (area under the curve, 0.95; 95% confidence intervals, 0.89-0.98; P<0.00005).

287 , and 54,400-46,050 cal BP (all at the 95.4% confidence level).

288 difference, 3.7 percentage points; 95% upper confidence limit, 12.56 percentage points; P=0.01 for no

289 90% confidence interval contained within the confidence limits of 80.00% and 125.00%.

290 sent the first reference catalog of 682 high-confidence lncRNAs based on analysis of strand-specific

291 hypermutable DNA regions to reconstruct high-confidence phylogenetic trees.

292 choice were obtained through trial by trial confidence ratings and were used to compute metacognitiv

293 Higher confidence ratings than the control condition were found

294 ees C and storage beyond 60 days and provide confidence regarding this commercially available NAAT fo

295 ows that 80% of features with high or medium confidence scores have ion dissociation patterns consist

296 model parameters by incorporating parameter confidence through Monte Carlo simulations and running a

297 llustrates how such data can add substantial confidence to target identification and validation analy

298 Diagnostic confidence was rated on a scale of 1 to 10.

299 at interact directly or indirectly with high confidence with chloroplast HSP22E/F under heat stress t

300 mmodate varying levels of pretrial biomarker confidence within the same platform structure and makes

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。